IL102571A - Pharmaceutical composition for the treatment of heart failure, containing an inhibitor of neutral endopeptidase together with an angiotensin- converting enzyme inhibitor - Google Patents
Pharmaceutical composition for the treatment of heart failure, containing an inhibitor of neutral endopeptidase together with an angiotensin- converting enzyme inhibitorInfo
- Publication number
- IL102571A IL102571A IL102571A IL10257192A IL102571A IL 102571 A IL102571 A IL 102571A IL 102571 A IL102571 A IL 102571A IL 10257192 A IL10257192 A IL 10257192A IL 102571 A IL102571 A IL 102571A
- Authority
- IL
- Israel
- Prior art keywords
- inhibitor
- pharmaceutical composition
- heart failure
- converting enzyme
- neutral endopeptidase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/744,208 US5225401A (en) | 1991-08-12 | 1991-08-12 | Treatment of congestive heart failure |
Publications (2)
Publication Number | Publication Date |
---|---|
IL102571A0 IL102571A0 (en) | 1993-01-14 |
IL102571A true IL102571A (en) | 1997-07-13 |
Family
ID=24991881
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL102571A IL102571A (en) | 1991-08-12 | 1992-07-21 | Pharmaceutical composition for the treatment of heart failure, containing an inhibitor of neutral endopeptidase together with an angiotensin- converting enzyme inhibitor |
Country Status (13)
Country | Link |
---|---|
US (1) | US5225401A (ja) |
EP (1) | EP0527624A3 (ja) |
JP (1) | JPH05194272A (ja) |
KR (1) | KR100241678B1 (ja) |
AU (1) | AU655649B2 (ja) |
CA (1) | CA2075671A1 (ja) |
HU (1) | HUT65691A (ja) |
IL (1) | IL102571A (ja) |
MX (1) | MX9204625A (ja) |
NO (1) | NO923130L (ja) |
NZ (1) | NZ243623A (ja) |
RU (1) | RU2080112C1 (ja) |
ZA (1) | ZA925698B (ja) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5552397A (en) * | 1992-05-18 | 1996-09-03 | E. R. Squibb & Sons, Inc. | Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase |
US5654294A (en) * | 1993-05-13 | 1997-08-05 | Bristol-Myers Squibb | Spiro lactam dual action inhibitors |
US5525723A (en) * | 1993-11-18 | 1996-06-11 | Bristol-Myers Squibb Co. | Compounds containing a fused multiple ring lactam |
CA2168066A1 (en) * | 1995-02-08 | 1996-08-09 | James R. Powell | Treatment of hypertension and congestive heart failure |
US5587375A (en) * | 1995-02-17 | 1996-12-24 | Bristol-Myers Squibb Company | Azepinone compounds useful in the inhibition of ACE and NEP |
US5877313A (en) | 1995-05-17 | 1999-03-02 | Bristol-Myers Squibb | Benzo-fused azepinone and piperidinone compounds useful in the inhibition of ACE and NEP |
US5635504A (en) * | 1995-06-07 | 1997-06-03 | Bristol-Myers Squibb Co. | Diazepine containing dual action inhibitors |
US5650408A (en) * | 1995-06-07 | 1997-07-22 | Karanewsky; Donald S. | Thiazolo benzazepine containing dual action inhibitors |
IT1277736B1 (it) * | 1995-12-28 | 1997-11-12 | Zambon Spa | Derivati tiolici ad attivita' inibitrice delle metallopeptidasi |
US5849681A (en) * | 1996-02-09 | 1998-12-15 | S. C. Johnson & Son, Inc. | Glass cleaner with enhanced anti-streaking properties |
SE9903028D0 (sv) | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
KR20020040795A (ko) * | 1999-08-30 | 2002-05-30 | 로버트 흐라이탁, 미쉘 베스트 | 심혈관 사고 예방용 레닌-안지오텐신 시스템 억제제의 용도 |
CA2330904C (en) * | 2001-01-11 | 2006-10-24 | Bernard Charles Sherman | Fosinopril sodium tablet formulation |
AU2002348276A1 (en) * | 2001-11-16 | 2003-06-10 | Bristol-Myers Squibb Company | Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein |
US7459474B2 (en) * | 2003-06-11 | 2008-12-02 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
US20050054731A1 (en) * | 2003-09-08 | 2005-03-10 | Franco Folli | Multi-system therapy for diabetes, the metabolic syndrome and obesity |
US7371759B2 (en) * | 2003-09-25 | 2008-05-13 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
US7420059B2 (en) | 2003-11-20 | 2008-09-02 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
US7273881B2 (en) | 2004-01-16 | 2007-09-25 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
US7888381B2 (en) | 2005-06-14 | 2011-02-15 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof |
US20070015839A1 (en) * | 2005-07-14 | 2007-01-18 | Franco Folli | Daily Dosage Regimen for Treating Diabetes, Obesity, Metabolic Syndrome and Polycystic Ovary Syndrome |
AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
US7592461B2 (en) | 2005-12-21 | 2009-09-22 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
CN101432025B (zh) * | 2006-03-21 | 2012-04-04 | 安米林药品公司 | 肽-肽酶抑制剂结合物及其使用方法 |
US20070238770A1 (en) * | 2006-04-05 | 2007-10-11 | Bristol-Myers Squibb Company | Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations |
EP2035450A2 (en) | 2006-05-26 | 2009-03-18 | Amylin Pharmaceuticals, Inc. | Composition and methods for treatment of congestive heart failure |
US7795291B2 (en) | 2006-07-07 | 2010-09-14 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method |
EP2089389A2 (en) | 2006-11-01 | 2009-08-19 | Bristol-Myers Squibb Company | Heterocyclic compounds as modulators of glucocorticoid receptor, ap-1, and/or nf-kappa-b activity |
JP2010508358A (ja) | 2006-11-01 | 2010-03-18 | ブリストル−マイヤーズ スクイブ カンパニー | グルココルチコイド受容体、AP−1、および/またはNF−κB活性の調節剤、並びにその使用 |
WO2008057862A2 (en) | 2006-11-01 | 2008-05-15 | Bristol-Myers Squibb Company | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF |
DK2170930T3 (da) | 2007-06-04 | 2012-11-05 | Synergy Pharmaceuticals Inc | Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
US8598314B2 (en) * | 2007-09-27 | 2013-12-03 | Amylin Pharmaceuticals, Llc | Peptide-peptidase-inhibitor conjugates and methods of making and using same |
JP2011522828A (ja) | 2008-06-04 | 2011-08-04 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
WO2009158380A1 (en) | 2008-06-24 | 2009-12-30 | Bristol-Myers Squibb Company | Cyclopentathiophene modulators of the glucocorticoid receptor, ap-1, and/or nf-kappa b activity and use thereof |
ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
KR102272746B1 (ko) | 2013-06-05 | 2021-07-08 | 보슈 헬스 아일랜드 리미티드 | 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법 |
WO2015027021A1 (en) | 2013-08-22 | 2015-02-26 | Bristol-Myers Squibb Company | Imide and acylurea derivatives as modulators of the glucocorticoid receptor |
EP4259189A4 (en) * | 2020-12-10 | 2024-02-28 | BaroPace, Inc. | TREATMENT OF DRUG-RESISTANT HYPERTENSION AND HEART FAILURE WITH PRESERVED EJECTION FRACTION BY COMBINED TREATMENT WITH STIMULATION OF BARORECEPTORS AND BETA-BLOCKERS |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LU88621I2 (fr) * | 1980-10-23 | 1995-09-01 | Schering Corp | Sandopril |
US4906615A (en) * | 1980-12-18 | 1990-03-06 | Schering Corporation | Substituted dipeptides as inhibitors of enkephalinases |
US4722810A (en) * | 1984-08-16 | 1988-02-02 | E. R. Squibb & Sons, Inc. | Enkephalinase inhibitors |
US4826816A (en) * | 1984-09-24 | 1989-05-02 | Schering Corporation | Antihypertensive compounds |
US4749688A (en) * | 1986-06-20 | 1988-06-07 | Schering Corporation | Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension |
EP0254032A3 (en) * | 1986-06-20 | 1990-09-05 | Schering Corporation | Neutral metalloendopeptidase inhibitors in the treatment of hypertension |
US4801609B1 (en) * | 1987-03-27 | 1993-11-09 | Mercapto-acylamino acid antihypertensives | |
CA1337400C (en) * | 1987-06-08 | 1995-10-24 | Norma G. Delaney | Inhibitors of neutral endopeptidase |
EP0361365A1 (en) * | 1988-09-30 | 1990-04-04 | E.R. SQUIBB & SONS, INC. | Aminobenzoic and aminocyclohexane-carboylic acid compounds, compositions, and their method of use |
EP0495822A1 (en) * | 1989-10-13 | 1992-07-29 | Schering Corporation | Carboxyalkyl dipeptide inhibitors of endopeptidases |
US5389610A (en) * | 1989-11-21 | 1995-02-14 | Schering Corporation | Carboxyalkylcarbonyl aminoacid endopeptidase inhibitors |
WO1991009840A1 (en) * | 1989-12-22 | 1991-07-11 | Schering Corporation | Mercaptocycloacyl aminoacid endopeptidase inhibitors |
-
1991
- 1991-08-12 US US07/744,208 patent/US5225401A/en not_active Expired - Lifetime
-
1992
- 1992-07-20 NZ NZ243623A patent/NZ243623A/en unknown
- 1992-07-21 IL IL102571A patent/IL102571A/xx not_active IP Right Cessation
- 1992-07-29 ZA ZA925698A patent/ZA925698B/xx unknown
- 1992-08-10 MX MX9204625A patent/MX9204625A/es not_active IP Right Cessation
- 1992-08-10 CA CA002075671A patent/CA2075671A1/en not_active Abandoned
- 1992-08-10 EP EP19920307287 patent/EP0527624A3/en not_active Withdrawn
- 1992-08-11 NO NO92923130A patent/NO923130L/no unknown
- 1992-08-11 RU SU5052259/14A patent/RU2080112C1/ru not_active IP Right Cessation
- 1992-08-11 KR KR1019920014386A patent/KR100241678B1/ko not_active IP Right Cessation
- 1992-08-11 AU AU20933/92A patent/AU655649B2/en not_active Ceased
- 1992-08-11 HU HU9202616A patent/HUT65691A/hu unknown
- 1992-08-12 JP JP4214965A patent/JPH05194272A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2093392A (en) | 1993-02-18 |
NO923130D0 (no) | 1992-08-11 |
HUT65691A (en) | 1994-07-28 |
IL102571A0 (en) | 1993-01-14 |
KR100241678B1 (ko) | 2000-03-02 |
EP0527624A2 (en) | 1993-02-17 |
ZA925698B (en) | 1993-03-02 |
NZ243623A (en) | 1994-04-27 |
RU2080112C1 (ru) | 1997-05-27 |
JPH05194272A (ja) | 1993-08-03 |
HU9202616D0 (en) | 1992-10-28 |
AU655649B2 (en) | 1995-01-05 |
MX9204625A (es) | 1993-04-01 |
KR930003912A (ko) | 1993-03-22 |
EP0527624A3 (en) | 1993-09-15 |
CA2075671A1 (en) | 1993-02-13 |
NO923130L (no) | 1993-02-15 |
US5225401A (en) | 1993-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL102571A (en) | Pharmaceutical composition for the treatment of heart failure, containing an inhibitor of neutral endopeptidase together with an angiotensin- converting enzyme inhibitor | |
BG97068A (bg) | Фармацевтичен състав и метод за постигане на терапевтичен ефект | |
MX9706069A (es) | Nuevos inhibidores de la trombina. | |
IL107207A0 (en) | Sustained release pharmaceutical compositions | |
NZ312950A (en) | Cell adhesion inhibitors that inhibit the binding of ligands to VLA-4 | |
IL117782A0 (en) | Tricyclic compounds | |
HUT78058A (hu) | A keratinocita növekedési faktor analógjai | |
ES8703089A1 (es) | Procedimiento para la obtencion de un medicamento que con contiene como sustencia activa la combinacion de dihidropiridinas con inhibidores ace | |
EP0975351A4 (en) | TREATMENT OF MULTIPLE Sclerosis BY TAKING OR INHALING COPOLYMER-1 | |
TR199802345T2 (xx) | Siklooksijenaz-2-arac�l� hastal�klarda g�nde bir kez tatbikat i�in bile�imler. | |
IE840301L (en) | Benzazocinone and benzazoninone derivatives | |
MY135057A (en) | Dolastatin 15 derivatives | |
ZA951974B (en) | Bradykinin antagonist peptides incorporating N-subsituted glycines | |
MX9710252A (es) | Utilizacion de al menos un peptido en una composicion cosmetica o para la preparacion de un medicamento. | |
HUP0001014A2 (hu) | Gasztrointesztinális lipáz inhibitorok felhasználása | |
MX9707683A (es) | Composiciones de combinacion que contienen benazepril o benazeprilat y valsartan. | |
MX9801190A (es) | Inhibidores de prolil endopeptidasa. | |
HK1014011A1 (en) | Cyclopeptolides | |
ZA979647B (en) | Heterocyclic compounds, compositions and uses. | |
HU9603489D0 (en) | Medical composition and process for producing it | |
NZ318627A (en) | Polyfluoroalkyl tryptophan tripeptide thrombin inhibitors | |
EP0910375A4 (en) | COMPOSITION BASED ON ENALAPRIL AND LOSARTAN | |
ZA979650B (en) | Heterocyclic compounds, compositions and uses. | |
ZA979645B (en) | Heterocyclic compounds, compositions and uses. | |
EA200100477A1 (ru) | Фармацевтическая композиция тнр и эналаприла |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
MM9K | Patent not in force due to non-payment of renewal fees |